# OnCo record resonate-2 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/resonate-2/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "resonate-2", "NCT01722487" ;
  schema:name "RESONATE-2"@en ;
  schema:description "RESONATE-2 showed that the oral BTK inhibitor ibrutinib kept untreated chronic lymphocytic leukaemia in check far longer than the old chemotherapy tablet chlorambucil in older patients, and helped them live longer, which brought targeted pills into first-line treatment of this leukaemia."@en ;
  schema:url <https://onco.cc/trials/resonate-2/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT01722487> ;
  onco:status "positive" ;
  onco:tag "subtype-trials" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/cll-treatment-naive/>, <https://onco.cc/cancers/cll/> ;
  onco:drugs <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/chlorambucil/> ;
  onco:companies <https://onco.cc/companies/abbvie/>, <https://onco.cc/companies/johnson-johnson/> ;
  onco:people <https://onco.cc/people/jan-burger/> .